Long-term exposure of HL60 cells to 1,25-dihydroxyvitamin D3 reduces their tumorigenicity: A model for cancer chemoprevention

Proceedings of the Society for Experimental Biology and Medicine

Volumn 215, Issue 4, 1997, Pages 399-404

  Wang, Xuening ^a   Ponzio, Nicholas M ^a   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENICITY; CELL STRAIN HL 60; CHEMOPROPHYLAXIS; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; SPLEEN CELL; SUNLIGHT; VITAMIN INTAKE;

ANIMALIA; MURINAE;

EID: 0030745438     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-215-44150     Document Type: Article

References (30)

1. Studzinski GP, McLane JA, Uskokovic MR. Signaling pathways for vitamin D-induced differentiation; implications for therapy of proliferative and neoplastic diseases. Crit Rev Eukaryot Gene Expr 4:229-254, 1993.
2. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16:200-257, 1995.
3. Studzinski GP, Moore DC. Vitamin D and retardation of cancer progression. In: Watson RR, Mufti SI, Eds. Nutrition and Cancer Prevention. CRC Press, pp257-282, 1996.
4. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 9:227-231, 1980.
5. Gorham ED, Garland CF, Garland FC. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Can J Public Health 80:96-100, 1989.
6. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis) Anticancer Res 10:1307-1312, 1990.
7. Studzinski GP, Moore DC. Sunlight - Can it prevent, as well as cause, cancer? Cancer Res 55:4011-4022, 1995.
8. Breslow N, Chan CW, Dhom G, Drury RAB, Franks LM, Gelleri B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 20:680-688, 1977.
9. Corder EH, Guess HA, Hulka BS. Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-472, 1993.
10. Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 54:1653-1656, 1994.
11. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW, Roberts AB, Sporn MB. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl) retinamide, and the vitamin D analogue Ro24-5531 for androgen promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 55:5621-5627, 1995.
12. 3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 116:605-611, 1983.
13. 3 in nude mice bearing transplantable human myelogenous leukemic cell lines. Exp Hematol 13:722-732, 1985.
14. 3. Cancer Res 47:21-25, 1987.
15. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-837, 1991.
16. 3 in vivo on human osteosarcoma. J Orthopaed Res 11:122-130, 1993.
17. 3 inhibits proliferation of human promyelocytic leukemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. Leuk Res 7:51-55, 1983.
18. 3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. Biochem Biophys Res Commun 117:86-92, 1983.
19. Studzinski GP, Bhandal AK, Brelvi ZS. A system for monocytic differentiation of leukemic cells HL 60 by 1,25-dihydroxycholecalciferol. Proc Soc Exp Biol Med 179:288-295, 1985.
20. 3. Exp Cell Res 224:312-322, 1996.
21. 3 resistant HL60 cells is preceded by reduced growth factor dependence and constitutive up-regulation of Sp1 and AP-1 transcription factors. Cancer Res 56:5513-5521, 1996.
22. 3 correlates with a reduced rate of maturation of DNA replication intermediates. Cancer Res 51:3451-3455, 1991.
23. 3. Cell Prolif 27:37-46, 1994.
24. Ponzio NM. Lymphocyte responses to syngeneic antigens. I. Enhancement of the murine autologous mixed lymphocyte response by polyethylene glycol. Cell Immunol 49:266-282, 1982.
25. Lin T-Z, Ponzio NM. Syngeneic B lymphoma cells provide a unique stimulus to natural killer (NK) cells in genetically low-NK SJL/J mice. J Leuk Biol 49:48-57, 1991.
26. Gallagher R, Collins S, Trujillo K, McCredie K, Aheam M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54:713-733, 1979.
27. Haller O, Hansson M. Kiessling R, Wigzell H. Role of nonconventional natural killer cell resistance against syngeneic tumor cells in vivo. Nature 270:609-611, 1977.
28. Nunn ME, Herberman RB. Natural cytotoxicity of mouse, rat and human lymphocytes against heterologous target cells. J Natl Cancer Inst 62:765-771, 1979.
29. 3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunology 150:2418-2430, 1993.
30. Long L, Rubin R, Baserga R, Brodi P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55:1006-1008, 1995.